US Broker Ratings

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Biotech with 25% Upside Potential

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a promising player in the biotechnology sector, has caught the eye of investors with its significant growth potential and innovative..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Navigating a Promising 43.13% Upside in Pain Management Pharmaceuticals

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) presents an intriguing opportunity for investors with its potential upside of 43.13%, as highlighted by recent analyst evaluations. Operating within the..

Myriad Genetics, Inc. (MYGN) Investor Outlook: Potential 94% Upside Amidst Challenging Metrics

For investors keeping a close watch on the healthcare sector, Myriad Genetics, Inc. (NASDAQ: MYGN) presents an intriguing case with a potential upside of 94.47%, according..

Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a 292% Potential Upside in the Biotechnology Sector

Humacyte, Inc. (NASDAQ: HUMA) is capturing the attention of investors with its promising potential in the biotechnology industry and a striking potential upside of 292.86%. Specializing..

PureTech Health plc (PRTC)

⚠️ No article content returned.

..

KalVista Pharmaceuticals, Inc. (KALV) Investor Outlook: Exploring the 130% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is catching the eye of investors with its impressive potential upside of 130.59%, according to analyst ratings. This biotech firm, headquartered..

ATAI Life Sciences N.V. (ATAI) Stock Analysis: Exploring a 296% Upside Potential in Mental Health Biotech

ATAI Life Sciences N.V. (NASDAQ: ATAI), a trailblazer in the biotechnology sector, offers an intriguing opportunity for investors with a strong focus on mental health treatments...

Sage Therapeutics, Inc. (SAGE) Stock Analysis: Exploring the 24% Potential Upside in Biotech

Sage Therapeutics, Inc. (NASDAQ: SAGE) offers a compelling opportunity for investors within the biotechnology sector, particularly those interested in the development and commercialization of brain health..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: A Biotech with Over 440% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a promising player in the biotechnology sector, is capturing investor attention with its ambitious gene therapy programs targeting rare and life-threatening..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Navigating Growth in Pediatric Orthopedics with a 72% Upside Potential

OrthoPediatrics Corp. (NASDAQ: KIDS), a key player in the healthcare sector, is making strides in the specialized field of pediatric orthopedic medical devices. As a company..

CeriBell, Inc. (CBLL) Stock Report: Harnessing a Potential 79.61% Upside in the Medical Devices Sector

CeriBell, Inc. (CBLL), a burgeoning player in the healthcare sector, is capturing investor attention with its innovative approach to neurological diagnostics. Based in Sunnyvale, California, this..

Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential

Investors with a keen interest in the biotechnology sector will find Replimune Group, Inc. (NASDAQ: REPL) a compelling opportunity. This clinical-stage biotech company is at the..

AMN Healthcare Services Inc (AMN) Stock Analysis: Navigating Challenges with a 22% Upside Potential

AMN Healthcare Services Inc (NYSE: AMN) has positioned itself as a key player in the healthcare staffing and solutions industry, specializing in providing technology-driven workforce solutions..

Pharming Group N.V. (PHAR) Stock Analysis: Unveiling a Potential 188.89% Upside for Investors

Pharming Group N.V. (PHAR), a Netherlands-based biopharmaceutical firm, is capturing investor attention with its promising growth trajectory and strategic collaborations aimed at addressing rare diseases. With..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech with 153% Potential Upside

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a burgeoning player in the biotechnology sector, stands out with a significant potential upside of 153.38%, according to the latest analyst..

Inventiva S.A. (IVA) Stock Analysis: Exploring a 247% Potential Upside in the Biotech Sector

Inventiva S.A. (NASDAQ: IVA), a clinical-stage biopharmaceutical company based in France, is capturing investor attention with its promising drug development pipeline and significant potential upside. Specializing..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Potential 347.63% Upside

Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company based in New York, has captured the attention of investors with its promising drug pipeline targeting..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 256% Upside in the Biotech Sector

Altimmune, Inc. (NASDAQ: ALT) is a clinical-stage biopharmaceutical company that has caught the eye of investors with its ambitious pipeline and notable potential upside. With a..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Is a 214% Upside Within Reach for This Biotech Innovator?

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, has captured the attention of investors with an eye-catching potential upside of 214.32%. Specializing in precision medicines..

Sonida Senior Living, Inc. (SNDA): An Investor Outlook on Revenue Growth and Potential Upside

Sonida Senior Living, Inc. (SNDA), a prominent player in the healthcare sector, operates within the medical care facilities industry, focusing on providing senior housing and related..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds